Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biocartis and VIB Join Forces

Published: Monday, December 09, 2013
Last Updated: Sunday, December 08, 2013
Bookmark and Share
Company will develop a new CRC assay for MSI biomarker detection.

Biocartis and VIB have announced their exclusive license agreement on a novel panel of microsatellite instability (MSI) biomarkers for several cancers, in particular colorectal cancer (CRC).

This agreement will enable Biocartis to develop a unique and user-friendly assay, whereby MSI biomarkers can simply and rapidly be detected by Biocartis’ molecular diagnostics platform Idylla™.

Biocartis’ innovative platform and oncology assays
Biocartis develops the innovative user-friendly diagnostic platform Idylla™, for the molecular analysis of clinical samples.

Biocartis also develops a wide range of clinically relevant tests for various diagnostic areas primarily in the field of oncology. For the development of a new assay for microsatellite instability, Biocartis joins forces with the world-renowned research institute VIB.

Novel MSI biomarkers for colorectal, ovarian and other cancers
Microsatellite instability (MSI) is one of the premier molecular markers in CRC but is also important in ovarian, endometrial and gastric cancers. MSI evolves as a result of inactivation of the DNA mismatch repair (MMR) system and can be found in approximately 15% of all CRCs.

A completely novel set of MSI-markers is now introduced by Prof. Dr. Diether Lambrechts (Vesalius Research Center, VIB, KU Leuven) through whole genome sequencing of colon and endometrial cancers with MMR deficiency.

Prof. Lambrechts commented: “We were able to prove that our novel set of markers has a higher specificity and sensitivity than the current golden standard for MSI. I am very excited about this collaboration with Biocartis, as the clinical application of these markers will facilitate the improved detection of tumors with MSI.”

New colorectal cancer assay for simple and rapid detection
As a result of the license agreement with VIB, Biocartis will develop a new CRC assay for MSI biomarker detection. Today, MSI-testing is vastly underused due to the technical complexity of the current laboratory-developed assays. The availability of a simple and user-friendly assay on Biocartis’ Idylla™ platform has the potential to unlock greatly this considerable market.

Geert Maertens, CSO at Biocartis, commented: “This agreement is a nice example of valorization of new biomarkers from centers of excellence such as the VIB-lab of Prof. Lambrechts. Together with our core panel of colon cancer mutations and the recently in-licensed EGFR S492R mutation from Hospital del Mar, we are building a superior and unique menu for colon cancers assays on our Idylla™ platform.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biocartis to Present BRAF Liquid Biopsy Data at ASCO Annual Meeting
BRAF mutations identified by Idylla™ from circulating tumor DNA in plasma associated with treatment response.
Thursday, June 04, 2015
Biocartis Announces Completion of EUR 30 Million Series E Equity Fundraising
Company poised for 2014 commercial launch.
Thursday, November 07, 2013
Biocartis and Hospital del Mar Join Forces
License agreement to develop diagnostic colon cancer test.
Monday, October 21, 2013
Scientific News
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!